We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Rectal Colonization by Klebsiella Leads to Different Risks for Bacteremia

By LabMedica International staff writers
Posted on 20 Jul 2021
Carbapenem-resistant Enterobacterales (CRE) represent a threat for public health, being among the top multidrug-resistant pathogens. More...
Intestinal colonization by CRE is a risk factor for developing subsequent infection.

In patients colonized by Klebsiella pneumoniae Carbapenemase (KPC)-producing Klebsiella pneumoniae (KPC-Kp), the rate of bloodstream infections (BSI) ranges from 8% to 23%, and specific factors for development of subsequent BSI have been identified. K.pneumoniae typically colonizes human mucosal surfaces of the oropharynx and gastrointestinal (GI) tract.

Infectious Disease specialists at the Pisan University Hospital (Pisa, Italy) and their colleagues carried out single-center, longitudinal, prospective, observational study involving consecutive adult patients with rectal colonization by CR-Kp admitted to the hospital from December 2018 to December 2019. After initial screening, all hospitalized patients were monitored through periodical rectal swabs on a regular basis (once a week in non-ICU and twice a week in ICU wards).

Rectal swabs were processed using three sequential steps: 1) molecular detection of bla genes involved in carbapenems resistance, 2) culture and pathogen identification, and 3) antibiotic susceptibility testing. Molecular screening was performed by the GeneXpert System Xpert-CARBA test (Cepheid, Sunnyvale, CA, USA). Species identification was performed using MALDI-TOF MS (Bruker Daltonics, Bremen, Germany). Antimicrobial susceptibility tests were performed with the SensiTitre system (Thermo Fisher Scientific, Waltham, MA, USA). Isolates were subjected to whole-genome sequencing (WGS) with an Illumina MiSeq platform (Illumina, San Diego, CA, USA). Rectal carriers were classified as: NDM, KPC, VIM and OXA-48.

The scientists reported that of 677 rectal carriers, 382/677 (56.4%) were colonized by NDM, 247/677 (36.5%) by KPC, 39/677 (5.8%) by VIM and 9/677 (1.3%) by OXA-48. Dissemination of NDM-KP was mostly sustained by ST147, while KPC-kp belonged to ST512. A higher rate of BSI was documented in NDM-compared to KPC-rectal carriers: 59/382, (15.4%) versus 20/247, (8.1%). Incidence rates of BSI/100 patients/month were significantly higher in the NDM (22.33) than in the KPC group (9.56). On multivariate analysis, multi-site extra-intestinal colonization, solid organ transplantation, invasive procedures, intravascular device, ICU, cephalosporin, fluoroquinolones and NDM rectal colonization (odds ratio [OR] = 3.27) were independently associated with BSI.

The authors concluded that their patients colonized by NDM-Kp are at higher risk of bacteremia compared to those colonized by KPC-Kp and the carbapenemase type is strongly related to the specific ST. Thus, the findings may reflect an increased virulence of the ST147 clone of Kp. The study was published on June 27, 2021 in the journal Clinical Microbiology and Infection.

Related Links:
Pisan University Hospital
Cepheid
Bruker Daltonics
Thermo Fisher Scientific
Illumina



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Scout\'s patented molecular technology delivers results matching high-complexity PCR 99% of the time (Photo courtesy of Scout Health)

STI Molecular Test Delivers Rapid POC Results for Treatment Guidance

An affordable, rapid molecular diagnostic for sexually transmitted infections (STIs) has the potential to be globally relevant, particularly in resource-limited settings where rapid, point-of-care results... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.